Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research

$300,000 in Research Grants Awarded as Part of its Ongoing Annual Research Awards Program TEMPE, Ariz.–(BUSINESS WIRE)–Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the … [Read more…]

MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease

MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg®. Xervyteg® has the potential if approved, to become the first microbiota therapeutic approved by the EMA and the first one in hemato-oncology globally. The MAA submitted to the … [Read more…]

Fi Unleashes the World’s First AI-Powered Smart Dog Collar, Built for Real-Time Health and Behavior Detection

Combining best-in-class GPS tracking with a comprehensive suite of AI-powered health and behavior detection, Series 3+ sets a new standard for connected dog care, paving the way for the future. NEW YORK–(BUSINESS WIRE)–Fi, the leader in smart pet technology, today announced the launch of its newest product: Fi Series 3+, the world’s first AI-powered collar … [Read more…]

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

MARLBOROUGH, Mass.–(BUSINESS WIRE)–#ZenoTOF–At ASMS 2025, SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands … [Read more…]

Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting

BEIJING–(BUSINESS WIRE)–#InnoCare–Latest data of InnoCare’s robust oncology pipelines were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and the pan-TRK inhibitor zurletrectinib (ICP-723). Oral Presentation Title: Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 … [Read more…]

Hyundai Card Becomes First in Asia to Achieve UL Solutions Healthy Building Verifications for Cultural and Leisure Facilities

Four iconic Hyundai Card structures earn the UL Verified Healthy Building Mark, demonstrating Hyundai Card’s commitment to creating healthier and more sustainable indoor environments for employees and guests. NORTHBROOK, Ill.–(BUSINESS WIRE)–UL Solutions (NYSE: ULS), a global leader in applied safety science, today announced that four properties operated by Hyundai Card, a leading South Korean credit … [Read more…]

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support … [Read more…]

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting … [Read more…]

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free … [Read more…]

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary … [Read more…]